Clinical outcomes of colchicine therapy following percutaneous coronary intervention in patients with acute coronary syndrome: the MACT (Mono Antiplatelet and Colchicine Therapy) prospective multicenter observational study

Bundang CHA General Hospital0 个研究点目标入组 490 人开始时间: 待定最近更新: 2024年7月23日

适应症

试验速览

暂无简介。

•1. A patient with positive troponin presenting with acute coronary syndrome who underwent insertion of ultrathin bioresorbable polymer sirolimus-eluting stents (Orsiro; Biotronik AG).
•2. A patient who has submitted a written informed consent for the research study.

•1. Patients under the age of 19.
•2. Patients experiencing cardiac arrest or cardiogenic shock.
•3. Patients currently taking or requiring potent CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir) or P-glycoprotein inhibitors (cyclosporine, ranolazine).
•4. Patients with the following concomitant conditions: myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia, severe gastrointestinal disorders, or genetic disorders such as galactose intolerance.
•5. Patients with hypersensitivity to colchicine therapy.
•6. Patients currently taking colchicine for another condition.
•7. Patients requiring anticoagulant therapy.
•8. Patients with liver disease of Child-Pugh class B or C.
•9. Patients with renal disease and a creatinine clearance <50 mL/min.
•10. Women of childbearing potential, breastfeeding, or pregnant women.
•11. Patients currently diagnosed with cancer or with a history of malignant tumors within the past 5 years.
•12. Patients with a life expectancy of less than 5 years.
•13. Contraindication to ticagrelor use (history of intracranial bleeding, active pathological bleeding, liver disease of Child-Pugh class B or C).

发起方

Bundang CHA General Hospital